222亿收购!体内CAR-T风口已至

并购菁英汇
Yesterday

6月30日,艾伯维宣布将收购体内CAR-T的明星公司Capstan Therapeutics,包括其潜在first-in-class体内抗CD19 CAR-T项目CPTX2309。CPTX2309当前处于I期临床,用于治疗B细胞介导的自身免疫性疾病。值得关注的是,公告中指出,艾伯维将以全现金方式支付此次交易的21亿美元(约合人民币150亿元)付款,足以见其势在必得。根据协议条款,艾伯维还将获得...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10